WallStreetZenWallStreetZen

NASDAQ: NUWE
Nuwellis Inc Stock

Open Broker Account
$0.14+0.00 (+0%)
Updated Dec 5, 2022
NUWE Price
$0.14
Fair Value Price
$1.28
Market Cap
$4.38M
52 Week Low
$0.10
52 Week High
$1.85
P/E
-0.1x
P/B
0.31x
P/S
0.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.85M
Earnings
-$16.98M
Gross Margin
55%
Operating Margin
-216.35%
Profit Margin
-216.5%
Debt to Equity
0.32
Operating Cash Flow
-$16M
Beta
0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NUWE Overview

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Zen Score

Industry Average (32)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NUWE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NUWE ($0.14) is undervalued by 89.16% relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NUWE ($0.14) is significantly undervalued by 89.16% relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NUWE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NUWE due diligence checks available for Premium users.

Be the first to know about important NUWE news, forecast changes, insider trades & much more!

NUWE News

Valuation

NUWE fair value

Fair Value of NUWE stock based on Discounted Cash Flow (DCF)
Price
$0.14
Fair Value
$1.28
Undervalued by
89.09%
NUWE ($0.14) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NUWE ($0.14) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NUWE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NUWE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.1x
Industry
62.76x
Market
21.63x

NUWE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
3.76x
NUWE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NUWE's financial health

Profit margin

Revenue
$2.1M
Net Income
-$3.9M
Profit Margin
-187.4%
NUWE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NUWE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$18.4M
Liabilities
$4.4M
Debt to equity
0.32
NUWE's short-term assets ($16.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUWE's short-term assets ($16.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUWE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NUWE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.3M
Investing
-$22.0k
Financing
-$15.0k
NUWE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NUWE vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
NUWE$4.38M-3.47%-0.10x0.31x
MYO$4.30M-4.69%-0.35x0.55x
BBLG$4.30M+0.36%-2.81x0.98x
VIVE$4.50M+2.69%-0.16x3.80x
AHPI$4.62M-1.71%-0.86x0.88x

Nuwellis Stock FAQ

What is Nuwellis's quote symbol?

NASDAQ: NUWE) Nuwellis trades on the NASDAQ under the ticker symbol NUWE. Nuwellis stock quotes can also be displayed as NASDAQ: NUWE.

If you're new to stock investing, here's how to buy Nuwellis stock.

What is the 52 week high and low for Nuwellis (NASDAQ: NUWE)?

(NASDAQ: NUWE) Nuwellis's 52-week high was $1.85, and its 52-week low was $0.10. It is currently -92.49% from its 52-week high and 37.62% from its 52-week low.

How much is Nuwellis stock worth today?

(NASDAQ: NUWE) Nuwellis currently has 31,531,650 outstanding shares. With Nuwellis stock trading at $0.14 per share, the total value of Nuwellis stock (market capitalization) is $4.38M.

Nuwellis stock was originally listed at a price of $3,022,992.06 in Feb 16, 2012. If you had invested in Nuwellis stock at $3,022,992.06, your return over the last 10 years would have been -100%, for an annualized return of -81.54% (not including any dividends or dividend reinvestments).

How much is Nuwellis's stock price per share?

(NASDAQ: NUWE) Nuwellis stock price per share is $0.14 today (as of Dec 5, 2022).

What is Nuwellis's Market Cap?

(NASDAQ: NUWE) Nuwellis's market cap is $4.38M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nuwellis's market cap is calculated by multiplying NUWE's current stock price of $0.14 by NUWE's total outstanding shares of 31,531,650.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.